Kornimate/medical-research-clean huggingface dataset:
initial ct findings and co-rads stage in covid-19

Conditions: Covid19; SARS-CoV Infection; Pneumonia, Viral

Summary: this study aims to determine whether patients with different real-time reverse transcriptase-polymerase chain reaction (pcr), chest computed tomography (ct) and laboratory findings have different clinical outcomes.

this study aims to determine the rates of pcr positivity and ct findings in hospitalized patients with a diagnosis of covid-19, to determine whether there is a difference in mortality and need for icu between patients grouped according to the pcr positivity and presence of ct findings, and to evaluate the effect of the co-rads stage on these outcomes. moreover, it is to compare the effects of inflammation and coagulation markers and co-rads stage on the severity of the disease

Eligibility criteria:
inclusion criteria: * aged 18 years and over, * having sars-cov-2 rt-pcr test and chest ct examinations performed at the time of application or within 24 hours after admission * rt-pcr positivity in nasopharyngeal swabs sample, and/or the presence of clinical and laboratory findings of sars-cov-2 infection and/or the presence of covid-19-compatible radiological findings in chest ct, and being diagnosed with covid-19 exclusion criteria: * patients with negative sars-cov-2 pcr test, pneumonia on ct but not given covid-19 treatment by not considering covid-19 by their doctor will not be included. * patients whose data are not available * patients with poor ct image quality * patients who were transferred to another hospital

Keywords: covid-19 sars-cov2 rt-pcr testing thorax computerized tomography mortality prognosis
efficacy of roflumilast on exacerbations in patients with non-cystic fibrosis bronchiectasis

Conditions: Exacerbation Copd; Bronchiectasis; Lung Function Decreased

Summary: roflumilast compare with placebo for decrease infected exacerbation in non-cystic bronchiectasis

efficacy and rct compare roflumilast vs placebo for 6 months in frequent infectious exacerbation in non-cystic bronchiectasis in thailand

Eligibility criteria:
inclusion criteria: * symptomatic bronchiectasis * history at least 2 exacerbation last year exclusion criteria: * comorbidity with chronic obstructive pulmonary disease

Keywords: bronchiectasis roflumilast exacerbation lung function
robotic trust-postural intervention for children with cerebral palsy

Conditions: Cerebral Palsy

Summary: the purpose of this study is to test the efficacy of a motor learning-based postural and reaching control intervention delivered with the robotic trunk-support-trainer (trust) compared to the same motor learning-based intervention delivered with static trunk support equipment in children with cerebral palsy (cp) classified as iii and iv with the gross motor function classification system (gmfcs).

this study is a prospective clinical randomized control trial (rct) in a group of 82 children with cerebral palsy. the experimental and control groups will receive effective postural-reaching training based on motor learning and control principles. in both groups, participants will engage in play and functional activities that elicit arm movement and challenge trunk postural control, and the motor tasks and activities will be progressed. the main difference is that the experimental group will be trained with trust in order to add postural task-progression via assistive force fields; which will be tailored to the child's sitting control balance status across training sessions. however, in the control group, postural task-progression will be addressed by lowering the level of rigid trunk support segment by segment across training sessions. the trunk subregion where the support is placed will depend on the child's trunk control ability. participants will be recruited from the united states.

Eligibility criteria:
inclusion criteria: * age 6-17 years * diagnosis of bilateral cp: diplegia, triplegia, or quadriplegia * gross motor function classification systems-expanded \& review (gmfcs) levels iii or iv * ability to sit 5s with trunk support between mid-ribs and pelvis (satco = 3-7) * cognitive capacity to follow basic verbal instructions (i.e., "do not put your hands on your lap" or "follow and reach the toy") exclusion criteria: * absent head control (satco = 1) * current medical illness unrelated to cp at the time of the study * severe dyskinesia that prevents the child from maintaining sitting and recovering balance during reaching movements * history of recurrent seizures (daily) or drug-resistance epilepsy * severe spinal deformities: scoliosis \>40◦ and/or kyphosis \>45◦ * spinal osteosynthesis or orthopedic surgery of spine, upper or lower extremities in the last 6 months * severe spasticity of biceps/triceps in both upper extremities (modified ashworth scale = 4) * local chemodenervation therapy in spastic muscles (e.g., botulinum toxin or phenol injections) in upper or lower extremities in the previous 3 months or planned during the study * other major surgeries in the previous 6 months (if medically contraindicated)

Keywords: posture reaching robotics motor learning motor control
suprapubic versus transurethral catheterization after rectal resection with low anastomosis for cancer in males

Conditions: Infection; Cancer

Summary: the purpose of this study is to compare the urinary tract infection rate on the four postoperative day between the 2 groups of patients who have undergone total mesorectal excision for cancer and low anastomosis, with either suprapubic or transurethral catheterization.


Eligibility criteria:
inclusion criteria: * male patients of at least 18 years of age * histologically proven rectal adenocarcinoma * stage t1-4 nx mx * with or without neoadjuvant treatment * tme and low anastomosis (colorectal or coloanal, stapled or handsewn) * with or without loop ileostomy * open or laparoscopic approach * patient and doctor have signed a study specific informed consent form exclusion criteria: * colonic and upper third rectal cancer (no or partial mesorectal excision) * abdominoperineal resection * associated prostate, and/or seminal glands and/or bladder resection * infected tumour, emergency surgery * epidural analgesia * patient with antibiotic therapy (other than prophylaxis) * previous treated/untreated known prostate or bladder carcinoma * patient with symptomatic preoperative voiding dysfunction (ipss score \>19) * medical history of bladder catheterization for obstruction, or urethral surgery * patient necessitating urinary output monitoring (impaired renal function etc) * patient deprived of liberty or under guardianship or incapable of giving consent * against the usual indications of suprapubic drainage and / or urethral sounding any known allergies to medical device materials. (p. ex. latex) and in general the known allergies to sterilizing agents (particularly oxide ethylene and its derivatives.
effect of repeated exposures to compressed air on patients with aids

Conditions: AIDS

Summary: the exposure of human beings to markedly altered environments (ambient pressure and inhaled gas mixtures) has profound effects on their innate immune capacity to effectively combat viral illnesses. this phase iia clinical trial examines the effects of an exposure to a 4 atmospheric environment has on hiv-infected humans whose clinical condition has progressed to formal aids status.


Eligibility criteria:
inclusion criteria: * cd4 count \<200 * viral load \> 5000 exclusion criteria: * opportunistic infection * concurrent neoplasm (see protocol) * immunomodulators * hiv vaccination * investigational hiv drugs (see protocol) * pregnant women * major organ transplant

Keywords: aids hiv hyperbaric chamber treatment experienced
cellular immunotherapy study for brain cancer

Conditions: Gliomas; Anaplastic Astrocytoma; Anaplastic Oligodendroglioma; Anaplastic Mixed Glioma; Glioblastoma Multiforme; Malignant Meningioma

Summary: the purpose of this research study to determine if treating recurrent malignant gliomas with another person's (donor) immune system cells known as actl cells, will be safe. this study will also try to determine if persons who receive actl's are more or less likely to survive their brain tumor than persons who had similar tumors in the past. approximately 15 patients will be enrolled at ucla.


Eligibility criteria:
inclusion criteria to participate in this clinical trial, patients must meet the following eligibility criteria: 1. subjects must have a histologically proven diagnosis of malignant glioma or meningioma and been treated with prior standard radiation and chemotherapy. there must be evidence of unequivocal progression by mri. 2. tumor must be amenable to resection, and surgical resection must be clinically indicated. 3. age at least 18 years. 4. karnofsky performance scale score \>60. 5. adequate hematologic function: a) systemic white blood cell count greater than 2 x 103/mm3, b) platelet count greater than 100,000/mm3, c) hematocrit greater than 25%. 6. adequate renal function, with creatinine less than two times the upper limit. 7. adequate hepatic function, with sgot, alkaline phosphatase, and total bilirubin \< 2x upper limit of normal. 8. patients must have an expected survival of at least three months. 9. patients must not have a history of htlv, hiv, syphilis by rpr, hepatitis b and c. 10. patients must sign an informed consent. exclusion criteria patients will be excluded from the trial if the patients: 1. have multifocal tumors, bihemispheric tumors, infratentorial tumors, or non-surgically accessible tumors. 2. have prior tumor resections where the ventricles were extensively breached. 3. are pregnant or breast-feeding women. 4. are females of child-bearing potential unable or unwilling to practice adequate birth control methods. 5. have contraindications for brain mri scanning (e.g., intra-ocular metal fragments, cerebral aneurysm clips, pacemaker). 6. have concurrent malignancy, excluding curatively treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix. 7. have concurrent systemic infection. 8. have any clinically significant, uncontrolled medical illness, as determined by the investigators. 9. are unwilling or unable to comply with procedures required in this protocol.

Keywords: recurrent grade iii or grade iv gliomas anaplastic astrocytoma anaplastic oligodendroglioma anaplastic mixed glioma glioblastoma multiforme biotherapy malignant meningioma
a randomized, double blind, placebo controlled trial l-carnitine and piracetam in the treatment of weakness, muscle fatigue and muscle pain in the postpoliomyelitis syndrome

Conditions: Postpoliomyelitis Syndrome

Summary: this protocol aims to assess of l-carnitine and piracetam to relieve weakness, muscle fatigue and muscle pain in patients with postpoliomyelitis syndrome.


Eligibility criteria:
inclusion criteria: * patients with postpoliomyelitis syndrome diagnosis confirmed over a year; * electromyography test compatible with poliomyelitis; * preserved ability to swallow medication; * oral communication ability preserved; * preserved ability to perform pedaling test in at least one lower limb affected by postpoliomyelitis syndrome; * ability to understand information about the study and to document the decision about participating in the trial by signing the informed consent form. exclusion criteria: * history of intolerance to l-carnitine or piracetam; * treatment with l-carnitine during the past 3 months; * treatment with piracetam or any other nootropics pyrrolidone derivatives, during the past three months; * anemia (hemoglobin reference range - men 13 to 17 g/dl and women 12 to 15 g/dl); * high level of glycated hemoglobin (\> 7.0%); * electrolyte imbalance (hypokalaemia - reference potassium concentration range: 3.5 to 5.6 mmol / l); * renal failure (creatinine reference range: 0.70 to 1.50 mg/dl); * urinary tract infection; * thyroid dysfunction (reference range: free t4: 0.54 to 0.67 mg/dl and tsh reference range: 0.5 to 5.5 μui/ml) or usual treatment with thyroid hormone supplementation; * cardiomyopathy; * uncontrolled hypertension; * known or suspected autoimmune disease; * confirmed pregnancy, or plans to get pregnant during the trial; * depression or bipolar affective disorders with moderate to severe episodes within the last twelve months; * insulin-dependent diabetes mellitus; * treatment with anticoagulant drugs over two weeks (including non-steroidal anti-inflammatory drugs (nsaids), warfarin, phenprocoumon, heparin); * usual cocaine or alcohol use; * any other condition judged by the investigator as a possibility to interfere on the participant's decision to be part of the study or to accomplish investigation procedures.

Keywords: postpoliomyelitis syndrome piracetam l-carnitine
safety of pci-32765 in chronic lymphocytic leukemia

Conditions: B-cell Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma

Summary: the purpose of this study is to establish the safety and efficacy of orally administered pci-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.


Eligibility criteria:
inclusion criteria: 1. for treatment-naive group only: men and women ≥ 65 years of age with confirmed diagnosis of cll/sll, who require treatment per nci or international working group guidelines 15-18 2. for relapsed/refractory group only: men and women ≥ 18 years of age with a confirmed diagnosis of relapsed/refractory cll/sll following previous therapy(ie, failed ≥ 2 previous treatments for cll/sll and at least 1 regimen had to have had a purine analog \[eg, fludarabine\] for subjects with cll) 3. for high-risk relapsed/ refractorygroup only: men and women ≥ 18 years of age with a confirmed diagnosis of relapsed/refractory cll/sll with suboptimal response to chemoimmunotherapy, defined as progression of disease within 24 months of initiation of a regimen containing at least a nucleoside analogue or bendamustine in combination with a monoclonal antibody or failure to respond to such a regimen. (note: a minimum of 2 cycles of chemoimmunotherapy required for eligibility) 4. ecog performance status of ≤ 2 5. willing and able to participate in all required evaluations and procedures in this study protocol including swallowing capsules without difficulty exclusion criteria: 1. prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease free for at least 2 years or which will not limit survival to \< 2 years 2. any immunotherapy, chemotherapy, radiotherapy, or experimental therapy within 4 weeks before first dose of study drug (corticosteroids for disease-related symptoms allowed but require 1-week washout before study drug administration) 3. central nervous system (cns) involvement by lymphoma 4. major surgery within 4 weeks before first dose of study drug 5. concomitant use of medicines known to cause qt prolongation or torsades de pointes 6. significant screening electrocardiogram (ecg) abnormalities including left bundle branch block, 2nd degree av block type ii, 3rd degree block, bradycardia, and qtc \> 470 msec 7. lactating or pregnant

Keywords: pci-32765 lymphoma, b-cell leukemia, lymphoid leukemia, b-cell bruton's tyrosine kinase
prospective study of the prognostic value of new markers in adults with alk-positive large anaplastic lymphoma

Conditions: Anaplastic Large Cell Lymphoma, ALK-Positive

Summary: the study aims to evaluate the prognostic value on the complete metabolic response rate (mcr), the incidence of relapse / progression, the progression free survival (pfs) and the overall survival (os). * at diagnosis * after the first cycle of choep (early evaluation) * at the end of treatment

alk-positive anaplastic large cell (anaplastic large-cell lymphoma, alcl) is a rare adult disease for which almost all published studies are retrospective. the overall survival (os) at 5 years varies from 70 to 87%. a recent international pooled analysis showed that the international prognostic index (ipi) had good predictive value for the pfs and the os. in children, new prognostic factors have been identified: the titre of circulating anti-alk antibodies (inverse correlation between the antibody titre and the prognosis), the detection of a npm-alk transcript in the blood at diagnosis (minimal disseminated disease, mdd); correlation between mdd positivity and pejorative prognosis) and its minimal residual disease (mrd), and the histological subtype (common versus small cells / lymphohistiocytic). the predictive value of the oncogenic profile of alk-positive alcl and circulating tumor dna will be studied in this study. * at diagnosis (before starting treatment): * cycle 2 day 1 (before starting cycle 2 treatment): * at the end of treatment evaluation: 40 patients treated with 6 cycles of choep every 3 weeks and 1 lumbar puncture at diagnosis with intrathecal prophylaxis with methotrexate will be included prospectively. during a 2-year period, relapses / progressions and patient deaths will be monitored for the calculation of the incidence of relapse / progression, progression free survival (pfs) and overall survival (os).

Eligibility criteria:
inclusion criteria: over 18 years old diagnosed with anaplastic large-cell lymphoma alk+ planned treatment : 6 cycles of choep 21 planned lumbar puncture at diagnosis or at the first cycle with intrathecal prophylaxis with methotrexate (15 mg) at the first cycle planned interim positron emission tomograph (pet)-scan after 3 cycles of treatment and at the end of treatment according to the center standard of care exclusion criteria: involvement of the central nervous system intent of autologous stem-cell transplant in first line
long term efficacy and safety of zoledronic acid treatment in patients with bone metastases

Conditions: Bone Neoplasms

Summary: this study is designed to monitor the safety and efficacy of long-term treatment with zoledronic acid by assessing the incidence of, renal impairment, osteonecrosis of the jaw(onj), overall safety and skeletal related events (sres) beyond 12 months treatment


Eligibility criteria:
inclusion criteria: * documented bone metastases from breast cancer, prostate cancer or multiple myeloma * prior treatment with zoledronic acid for 1-2 yrs * life expectancy of at least 6 months exclusion criteria: * prior treatment with bisphosphonates other than zoledronic acid * abnormal kidney function * current or previous dental problems or planned dental surgery * pregnant or likely to become pregnant during the study other protocol-defined inclusion/exclusion criteria may apply

Keywords: prostate cancer breast cancer multiple myeloma zoledronic acid bone metastases skeletal related events (sres) renal impairment osteonecrosis of the jaw (onj) bone involvement multiple myeloma (mm)
iop fluctuations in primary open angle glaucoma patients before and after deep sclerectomy

Conditions: Primary Open Angle Glaucoma

Summary: primary open angle glaucoma (poag) is associated with inadequate drainage of the aqueous humor via the trabecular meshwork through the schlemm's canal towards the systemic circulation. this may lead to an increase in iop and may damage the optic nerve. the purpose of glaucoma management is to lower iop in order to prevent progression of the optic neuropathy and subsequent visual loss. firstline treatment usually includes iop-lowering drug therapy. however, if iop remains uncontrolled and/or the optic nerve damage progresses despite controlled iop, surgery may be indicated. deep sclerectomy (ds) is a non-penetrating surgical procedure for the treatment of open angle glaucoma that allows the enhancement of the aqueous outflow by removing part of the inner wall of schlemm's canal and trabecular meshwork. ds was shown to achieve a good control on iop over the long term. the purpose of this study is to assess the 24-hour iop fluctuation profile recorded with triggerfish in patients with poag before and after ds.


Eligibility criteria:
inclusion criteria: * diagnosis of poag * documented glaucomatous vf damage with mean defect (md) \> 3 db * progressing glaucomatous damage justifying a ds * aged ≥18 years, of either sex * not more than 4 diopters spherical equivalent on the study eye * not more than 2 diopters cylinder equivalent on the study eye * have given written informed consent, prior to any investigational procedures exclusion criteria: * corneal or conjunctival abnormality precluding contact lens adaptation * severe dry eye syndrome * patients with allergy to corneal anesthetic * patients with contraindications for silicone contact lens wear * patients not able to understand the character and individual consequences of the investigation * participation in other clinical research within the last 4 weeks * any other contra-indication listed in the triggerfish user manual

Keywords: glaucoma deep sclerectomy
efficacy and safety of sph4336 in combination with endocrine therapy in breast cancer patients with brain metastases.

Conditions: Breast Cancer Brain Metastases

Summary: this study evaluated the safety and efficacy of sph4336 in combination with endocrine therapy in breast cancer patients with brain metastases.


Eligibility criteria:
inclusion criteria: 1. patients who voluntarily participate in this study, completely understand this study, and voluntarily sign the informed consent form (icf). 2. ecog (eastern cooperative oncology group) performance status score of 0 or 1. 3. life expectancy ≥ 3 months. 4. patients with locally advanced or metastatic breast cancer who are unable to receive radical surgeries/other local therapies. 5. at least one measurable lesion . 6. laboratory test results meet the relevant requirements for organ function. 7. subjects who agree to take effective contraceptive measures. exclusion criteria: 1. inflammatory breast cancer. 2. patients unsuitable for endocrine therapy at the investigator's discretion. 3. have a history of other malignancies prior to the start of study treatment. 4. taking anti-tumor traditional chinese patent medicines at the time of signing the icf. 5. patients who underwent a surgery prior to the start of study treatment, and have not yet recovered from adverse reactions of the surgery. 6. patients who participated in a clinical trial and received other investigational drugs before the start of study treatment. 7. pregnant or lactating women. 8. history of myocardial infarction, unstable angina pectoris, severe arrhythmia, and symptomatic congestive heart failure before the start of study treatment; ≥ nyha (new york heart association) class ii; qtcf≥ 470 ms; left ventricular ejection fraction ≤ 50%. 9. history of ischemic stroke or severe thromboembolic disease before the start of study treatment. 10. hepatitis b surface antigen positive and hbv (hepatitis b virus) dna \> 2,000 iu/ml or \> 10(4) copies/ml; hcv (hepatitis c virus) antibody positive and hcv rna positive; or known hiv infection. 11. history of severe allergic diseases, history of severe drug allergies, or known allergy to any ingredient of the investigational product. 12. presence of diseases or conditions that may impact drug administration or gastrointestinal absorption before the start of study treatment. 13. presence of uncontrolled infections before the start of study treatment. 14. known history of drug abuse, excessive drinking, or illegal drug use; history of confirmed neurological or mental disorders. 15. presence of other diseases that the risks of receiving the study treatment outweigh its benefits, as determined by the investigator, or any other reason for which patients are ineligible for the study as assessed by the investigator.